On May 17, 2022, the U.S. Food and Drug Administration (FDA) amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine. This amendment authorizes administration of a single booster dose to children ages five through 11 years old after completion of a primary series with the Pfizer-BioNTech COVID-19 vaccine. On May 19, 2022, the Advisory Committee on Immunization Practices (ACIP) met and voted to approve a recommendation stating, “A single Pfizer-BioNTech COVID-19 vaccine booster dose is recommended for persons ages 5-11 years at least five months after the primary series, under the FDA’s Emergency Use Authorization.”
A technical bulletin, published on May 25, 2022, by the Nevada Department of Health and Human Services, summarizes the recent Pfizer-BioNTech COVID-19 vaccine booster dose recommendation for children. Children eligible to receive the recommended Pfizer-BioNTech COVID-19 vaccine booster dose include:
- Any individual ages 5 through 11 years old, at least five months after completion of a two-dose Pfizer-BioNTech COVID-19 vaccine primary series; and
- Any moderately to severely immunocompromised individual ages 5-11 years old, at least three months after completion of a three dose Pfizer-BioNTech COVID-19 vaccine primary series.
Full details are available in the most recent technical bulletin on the web page linked here.For more updates about medical and health-related facility licensure, visit the
Bureau of Health Care Quality and Compliance blog site.